-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $195

Benzinga·07/07/2026 15:42:18
Listen to the news
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $183 to $195.